Navigation Links
Vicus Therapeutics' Chief Executive Officer to Participate in BIOTECH 2007 Expert Panels
Date:10/4/2007

MORRISTOWN, N.J., Oct. 4 /PRNewswire/ -- Vicus Therapeutics, LLC, an oncology-focused, clinical-stage, biopharmaceutical company, today announced that John Maki, President and Chief Executive Officer, will participate in two panel discussions titled "Outsourcing: Best Practices and Lessons Learned from an Industry Perspective" and "Exit Strategies: Managing Risk and Reward" at BIOTECH 2007 on Monday, October 8, 2007. The sessions will run from 9:00 a.m. to 10:15 a.m. ET and from 12:30 p.m. to 1:45 p.m. ET, respectively, at the Loews Hotel in Philadelphia, PA.

About BIOTECH 2007

BIOTECH 2007, which is hosted by the BioNJ and Pennsylvania Bio, is designed to enhance the growth and development of the bioscience industry in the New Jersey and Pennsylvania regions. It is an opportunity for entrepreneurs, researchers and executives of emerging and large companies to network and share ideas, strategies and experiences.

About Vicus Therapeutics

Vicus Therapeutics is a privately-held, biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of cancer supportive care indications with an initial focus on cachexia. Vicus' strategy involves combining individual generic drugs that have previously received regulatory approval for other indications and thus have established post-marketing safety records. Vicus leverages its proprietary science to design and patent novel drug combinations that work together to reverse the body's maladaptive responses to cancer and its treatment. Vicus' lead combination product candidate, VT-122, is in Phase 2 clinical trials for the treatment of cancer cachexia in patients with advanced lung cancer. Additionally, Vicus has preclinical-stage combination product candidates being evaluated for the treatment of oral mucositis and cancer fatigue. Vicus' development programs are powered by its network of leading clinical investigators and partners in the US, India and Japan. This international network drives the high quality, rapid and cost effective clinical development of Vicus' product candidates.

For additional information, go to the Company's website:

http://www.vicustherapeutics.com


'/>"/>
SOURCE Vicus Therapeutics, LLC
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. State technology chief endorses IT audit recommendations
3. Fusion 2007: CA chief says IT complexity raises risk
4. Web-Based Learning Developed under new Chief Education Officer
5. Chemical-petroleum executive joins Virent Energy board
6. Visions: Matheys says CIO role is good training for executive suite
7. Biotech executive books a career flight thats closer to home
8. CEOs Gone Wild? Risks and rewards in the executive suite
9. Early-stage executives hear from investors
10. Pedlar the latest executive to leave Merge
11. Financial executives to launch Madison chapter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... and ROCKVILLE, Md. , March ... of Maxwell Biotech Venture Fund (MBVF), today announced positive ... added to the standard drug therapy regimen in patients ... small molecule drug discovered by scientists at Sequella, Inc. ... Institutes of Health. A total of ...
(Date:3/24/2017)... 2017 Agenus Inc. (NASDAQ: AGEN), an immuno-oncology ... cancer vaccines, today announced participation at the following conferences: ... Blair and Maidstone Life Sciences conference "Cancer Immunotherapy Conference" ... New York, NY . Agenus will participate ... 9:40 am: Robert B. Stein , M.D., Ph.D., ...
(Date:3/23/2017)... 23, 2017  SeraCare Life Sciences, Inc., a ... vitro diagnostics manufacturers and clinical laboratories, is ... multiplexed Inherited Cancer reference material ... next-generation sequencing (NGS). The Seraseqâ„¢ Inherited Cancer DNA ... from industry experts to validate the ability ...
(Date:3/23/2017)... YORK , March 23, 2017 ... ... of death, putting significant strain on health care systems, in ... cancer diagnoses rises, so too does the development of innovative ... minimum side effects. Among the many types of cancer treatments, ...
Breaking Biology Technology:
(Date:2/28/2017)... Germany , February 28, 2017 News ... ... Amsterdam from 14 to 16 March, Materna ... destination, and show how seamless travel is a real benefit for ... has added biometrics to their passenger touch point solutions to take ...
(Date:2/22/2017)... 2017 With the biometrics market to ... four technologies that innovative and agile startups must ... in the changing competitive landscape: multifactor authentication (MFA), ... "Companies can no longer afford to ... Dimitrios Pavlakis , Industry Analyst at ABI ...
(Date:2/13/2017)... , Feb. 13, 2017  RSA Conference -- ... platform that is designed to enhance fraud detection ... release in the RSA Fraud & Risk Intelligence ... organizations to leverage additional insights from internal and ... to better protect their customers from targeted cybercrime ...
Breaking Biology News(10 mins):